Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
Cytokinetics stock last closed at $64.18, up 1.41% from the previous day, and has increased 32.25% in one year. It has overperformed other stocks in the Biotechnology industry by 0.67 percentage points. Cytokinetics stock is currently +118.97% from its 52-week low of $29.31, and -9.58% from its 52-week high of $70.98.
There are currently 122.26M CYTK shares outstanding. The market capitalization of CYTK is $7.85B. In the last 24 hours, 1.15M CYTK shares were traded.
You need a brokerage account to access the NASDAQ market and buy CYTK shares.
Based on our research, eToro is the best place to buy stocks. Here's why:
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've chosen the best brokerage, the next step is to fill out some personal info so you are able to invest in CYTK stock today.
Now that you have created your account on the best stock trading app, you need to deposit funds:
Check out the walkthrough below for more details transferring funds into your new investment account.
After you have identified the best place to buy Cytokinetics stock, it's important to analyze their stock prior to investing, so you can comprehend the risk and opportunity.
WallStreetZen was created to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on CYTK's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CYTK's fair value.
You can access more valuation research on CYTK's stock here.
Out of 13 sell side analysts who track CYTK, the consensus analyst rating on Cytokinetics is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Joseph Pantginis, a top 6% analyst from HC Wainwright & Co. maintains CYTK with a buy rating and raises their CYTK price target from $120.00 to $136.00, on Dec 22, 2025.
Paul Choi, a top 29% analyst from Goldman Sachs upgrades CYTK to a strong buy rating and raises their CYTK price target from $55.00 to $95.00, on Dec 19, 2025.
Goldman Sachs's Paul Choi upgraded their rating on Cytokinetics (NASDAQ: CYTK) from Hold to Strong Buy on 2025/12/19. The analyst also raised their price target by 72.7% from $55 to $95.
According to Choi, Cytokinetics' aficamten, renamed Myqorzo, has been approved by the FDA for the treatment of people with symptomatic obstructive hypertrophic cardiomyopathy.
The analyst detailed that this medication improves functional capacity and symptoms.
Choi said the label is in line with expectations for an incrementally differentiated REMS program and looks slightly better than Bristol Myers Squibb Co.'s Camzyos.
Symptomatic obstructive hypertrophic cardiomyopathy is a form of heart disease where the heart muscle becomes abnormally thick, obstructs blood flow out of the heart, and causes noticeable symptoms such as shortness of breath, chest pain, or fainting.
Mayank Mamtani, a top 3% analyst from B. Riley Securities reiterates CYTK with a strong buy rating and raises their CYTK price target from $80.00 to $90.00, on Nov 10, 2025.
Jason Zemansky, a top 7% analyst from Bank of America maintains CYTK with a hold rating and raises their CYTK price target from $52.00 to $56.00, on Oct 2, 2025.
Cory Kasimov, a top 18% analyst from Evercore ISI Group maintains CYTK with a buy rating and raises their CYTK price target from $60.00 to $80.00, on Sep 3, 2025.
You can dive deeper into what analysts are forecasting on the Cytokinetics stock forecast page.
Last year, CYTK revenue was $87.21M. During the last five year, CYTK's revenue has gone up by 9.93% per year. This was slower than the Biotechnology industry average of 44.77%.
You can research CYTK's earnings and revenue performance here.
Over the last year, insiders at CYTK have sold more shares than they have bought.
Robert I. Blum, President CEO of CYTK, was the latest CYTK insider to buy. They bought $365,029.09 worth of CYTK shares on Dec 22, 2025.
Dig into more about who owns CYTK shares here.
No, Cytokinetics doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
There are two primary options:
Hit the Open Trade button and eToro will place the order.
If you require additional info about buying stocks on eToro, click the helpful video below:
Now that you own some CYTK shares, you'll want to stay up-to-date on your investment.
Create a watchlist to see the latest developments about your CYTK stock.
To reiterate, here are the 6 steps for buying Cytokinetics stock:
If you need a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep track of your investment in Cytokinetics, create a watchlist today.